Hallandale is $199 monthly or $510 for 3 months, all doses. Treatment and pharmacy availability are subject to provider review and applicable state availability.
Provider-reviewed compounded Tirzepatide — a dual GLP-1/GIP receptor agonist — prescribed after clinician review, with personalized dosing support and discreet delivery. No insurance required.
Hallandale is $199 monthly or $510 for 3 months, all doses. Treatment and pharmacy availability are subject to provider review and applicable state availability.
Compounded Tirzepatide is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or quality. It is not the same as, and is not a generic version of, FDA-approved Zepbound® or Mounjaro®. Prescription required following provider review. Not all patients qualify. Results vary.
The compounded products listed have not been evaluated or approved by the FDA for quality, safety or efficacy.
By continuing, you acknowledge this disclosure. Premier Element Group operates in compliance with all applicable federal and state regulations.